Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $1.0 million.

  • Spero Therapeutics' Share-based Compensation fell 5134.63% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 4182.45%. This contributed to the annual value of $7.8 million for FY2024, which is 175.24% down from last year.
  • Latest data reveals that Spero Therapeutics reported Share-based Compensation of $1.0 million as of Q3 2025, which was down 5134.63% from $714000.0 recorded in Q2 2025.
  • Spero Therapeutics' Share-based Compensation's 5-year high stood at $3.2 million during Q1 2022, with a 5-year trough of $714000.0 in Q2 2025.
  • In the last 5 years, Spero Therapeutics' Share-based Compensation had a median value of $2.0 million in 2024 and averaged $2.0 million.
  • In the last 5 years, Spero Therapeutics' Share-based Compensation soared by 11450.55% in 2021 and then crashed by 6620.92% in 2025.
  • Quarter analysis of 5 years shows Spero Therapeutics' Share-based Compensation stood at $2.9 million in 2021, then fell by 14.72% to $2.5 million in 2022, then fell by 20.02% to $2.0 million in 2023, then dropped by 24.74% to $1.5 million in 2024, then plummeted by 30.27% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $714000.0 for Q2 2025, and $1.6 million during Q1 2025.